Mendelspod Podcast

24:49

Why Childhood Cancers Need Their Own Gene Panel: Tim...

Mendelspod Podcast ·

2017/09/21

When we first talked with Tim Triche of LA Children's Hospital, we found out he was a bit of an outlier among cancer researchers. He was an advocate for poking around in the non-coding RNA.Today we welcome Tim back to the show to talk about a new gene panel that he has designed specifically for childhood cancers. It’s a first of its kind and was modeled quite closely on the gene panel for the NCI’s MATCH trial.The new panel has both a DNA and an RNA component, and the RNA side is by far the

en

24:44

Exploring the Exome and the Future of Genomics with...

Mendelspod Podcast ·

2017/09/13

Back in 2009, University of Washington professor, Jay Shendure, wrote a definitive paper offering up a roadmap for exome sequencing. Since then, the cost of sequencing has come down so far that many have debated whether or not to do whole genome sequencing vs. just the exome. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

20:29

August 2017 Review with Nathan and Laura: CAR-T...

Mendelspod Podcast ·

2017/09/01

Back from summer vacation, Nathan and Laura are smoking hot as they look back over some exciting headlines.The summer boiled over with plenty to talk about, but it was just this week that delivered most of the news for our discussion today. Novartis’ gene therapy based on CAR-T technology was approved Wednesday, making it the first gene therapy to be approved ever in the US. Analysts will be trying to figure out how high high is when it comes to the price tag, but Nathan and Laura explain why this

en

26:15

The First In-Human Gene Editing Trial in the U.S. -...

Mendelspod Podcast ·

2017/08/08

The challenge for the first ever in-human gene editing trial, according to today’s guest, is with the delivery to the body.“At the moment, the easiest place to deliver your gene or genome editing is to the liver, using AAV which are viruses that seek out and go to the liver cells," says Sandy Macrae, the CEO of Sangamo Therapeutics.Sangamo is known for two things: They have pioneered the commercialization of an older gene editing technology called Zinc Fingers. And they have done a lot of work in

en

25:24

Thermo, Pfizer, and Novartis Pull Off a First for NGS...

Mendelspod Podcast ·

2017/08/03

Today we get to bring you a feel good story, one of the major achievements so far in precision oncology. Three large companies—Thermo Fisher, Pfizer, and Novartis—put aside their differences to come together for patients.The patients are those who suffer from non-small cell lung cancer. In June, the FDA approved for the first time an NGS panel with multiple genes for multiple drugs that treat this kind of cancer. This is a public episode. If you'd like to discuss this with other subscribers or get

en

27:01

Making Genetic Testing Mainstream Medicine with Sean...

Mendelspod Podcast ·

2017/08/01

Invitae appointed their co-founder Sean George as CEO earlier this year. He joins us to share his bold vision for the field of genetic testing. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:46

Need Better Standards for Your Clinical Assays? NIST...

Mendelspod Podcast ·

2017/07/27

The life science tools space is flourishing. Biomedical research output is at an all time high. Today’s guest says there are over 40,000 papers published each year on cancer biomarkers.But very few of those become commercialized tests. Why? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

33:22

Turning on Your DNA with Justin Kao, Helix

Mendelspod Podcast ·

2017/07/25

They’re getting a lot of buzz this week. We’re pleased to have Justin Kao, a co-founder of Helix on the program today for the first time. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

20:35

Will This New Nano Technology Be the Microarray of...

Mendelspod Podcast ·

2017/07/20

Barrett Bready is back on the program. He’s the CEO of Nabsys, a company with some new technology for genome mapping.Originally Nabsys had been working to develop nanopore sequencing, but after a recent reboot has become focused on scaling up scientists' ability to read structural genomic information. Barrett compares Nabsys’ new multiplex technology for genome mapping to the improvement of arrays over single nucleotide (SNP) detection. This is a public episode. If you'd like to discuss this with

en

31:41

George Church on What Comes After CRISPR

Mendelspod Podcast ·

2017/07/13

George Church joins us today. He’s the Robert Winthrop Professor of . . . . well, he’s George Church. And he confirms that, yes, a movie called “Woolly" is being made about his lab. In the next breath, he reminds us (and himself?) that less than 1% of his press is about the woolly mammoth. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

23:56

Is CRISPR Controversy Science or Spin? June 2017...

Mendelspod Podcast ·

2017/06/30

It’s the end of the month--and the half year mark--so we open up today's monthly discussion with Nathan and Laura to include some of the headlines we’ve missed this year.Last month a paper was published warning about the off target effects when using CRISPR. Laura and Nathan agree the kerfuffle which exploded into this month was more about Wall Street than adding anything new to science.Remember the technology we used before CRISPR? Sangamo Biosciences launched the first ever “in vivo” (in human)

en

21:44

We Need a Google Maps for Metagenomics, Says Rob...

Mendelspod Podcast ·

2017/06/27

When will we see the results of microbiome research in our every day lives? And what will that look like?Rob Knight joins us for the first time today. He’s a professor at UC San Diego and Director of the Center for Microbiome Innovation. He is well known for co-authoring a paper showing that the microbial populations in the guts of obese mice differentiate from those in lean mice. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

20:49

Move Over PDL1: New Test Combo Adds RNAseq to Better...

Mendelspod Podcast ·

2017/06/22

Reports from ASCO, the nation’s biggest cancer conference, this year again were full of stunning stories about the success of older and new immuno therapies. The race has never been hotter for biomarkers to target patient groups. Most of this new class of drugs--which harnesses the immune system to go after the cancer--inhibit an immune checkpoint called programmed cell death protein 1 or PDL1. So frontline cancer treatment these days typically includes a test for the PDL1 biomarker. This is a

en

26:40

The Last Major Disease To Be Studied? Ron Davis of...

Mendelspod Podcast ·

2017/06/15

Let’s say you’re a biomedical researcher looking for a place to make your mark. You find out that there is still a major disease that affects more than 2 million people in the US, and we still know virtually nothing about this disease at the molecular level. Wouldn't that stand out? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

28:47

On Bioinformatics Data Sharing and Collaboration:...

Mendelspod Podcast ·

2017/06/08

What does it take to collaborate in genomics?A platform, for one thing. Over the past few years bioinformaticians have been speculating about a dominant "go to” site that would serve the software needs of those in genomics. Would it be a private company, a Google of genomics? Or would it be a non profit consortium? Would it be created at the government level? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit

en

23:15

Grail Merger, Genomic Autopsies, Overtreatment Alarm,...

Mendelspod Podcast ·

2017/06/01

Is Grail already merging? Genomic autopsies? Does the House's new healthcare bill turn mere genetic risk into pre-conditions? Nathan and Laura are back to find meaning in the rush of May's headlines.Laura cites a disturbing survey of over 2,000 women diagnosed with breast cancer that found half of them had unnecessary double mastectomies after genetic testing. She says unabashedly, “In big letters, it’s an ADVERTSIMENT FOR GENETIC COUNSELING.”Speaking of alarms, Nathan says attorney Joel

en

25:05

Is Population Medicine Failing Us? Michel Accad

Mendelspod Podcast ·

2017/05/25

Is health the same thing for an individual as it is for a population? This question goes to the foundation of how we practice medicine today and that of most of genomic research.Michel Accad is a cardiologist in San Francisco and the author of a new book, Moving Mountains: A Socratic Challenge to the Theory and Practice of Population Medicine, in which he uses Socrates to spar with Geoffrey Rose, a British physician and one of the architects of modern medicine. This is a public episode. If you'd

en

30:10

Deep Omics Profiler, Mike Snyder, Now Turns to Wearables

Mendelspod Podcast ·

2017/05/18

Mike Snyder is well known in the genomics community for his iPOP (integrated personal omics profiling) study. Profiling himself with hundreds of thousands of measurements each day over a period of seven years and a group of a hundred others for about three years, he and his team at Stanford have shown that sequencing and other omics data can be used to predict Type II diabetes, cancer, heart problems and other disease. He’s also published numerous papers comparing NGS instruments. Now he is

en

27:23

Over $1 Billion Invested this Past Year: Synthetic...

Mendelspod Podcast ·

2017/05/11

What does it take to make it in synthetic biology in 2017? This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

en

22:23

Green Light for DTC, Blood Mammograms, and Ancient...

Mendelspod Podcast ·

2017/05/01

For genomics nerds, April 2017 will be remembered as the date when the FDA adopted a more open policy towards 23andMe and direct-to-consumer (DTC) genetic testing. What does this decision mean, and just where is the FDA drawing the line? A genetic counselor herself, Laura found the decision “head turning.”“There’s lots of reasons why some genetic counselors are not going to be thrilled to deal with everyone’s 23andMe results,” she says. This is a public episode. If you'd like to discuss this with

en

All Episodes

Similar Podcasts

Mendelspod Podcast

Theral Timpson

DMCN Journal

John Wiley & Sons Ltd

汪诘：科学有故事（主打）

科学有故事

天方烨谈

基因频道

Homesteading and Permaculture by Paul Wheaton

paul wheaton